Luteolin prevents irinotecan-induced intestinal mucositis in mice through antioxidant and anti-inflammatory properties.
Thaise BoeingPriscila de SouzaSilvia SpecaLincon Bordignon SomensiLuisa Nathália Bolda MarianoBenhur Judah CuryMariana Ferreira Dos AnjosNara Lins Meira QuintãoJosepmaria ArgemiPierre DesreumaxLuisa Mota da SilvaSérgio Faloni de AndradePublished in: British journal of pharmacology (2020)
Luteolin prevents intestinal mucositis induced by irinotecan and therefore could be a potential adjunct in anti-tumour therapy to control this adverse effect, increasing treatment adherence and consequently the chances of cancer remission.
Keyphrases
- anti inflammatory
- radiation induced
- papillary thyroid
- oxidative stress
- diabetic rats
- mouse model
- chemotherapy induced
- squamous cell
- disease activity
- high fat diet induced
- stem cells
- squamous cell carcinoma
- type diabetes
- emergency department
- radiation therapy
- risk assessment
- young adults
- replacement therapy
- combination therapy
- weight loss
- insulin resistance
- glycemic control